Fig. 4
(A-J) Correlations between MCP-1, circadian patterns and neurological outcome humans
(A) MCP-1 concentrations in culture medium at ZT2 (= 2 h after medium change) after 1 h treatment with 100 µl blood in PMG (Hmox1fl/fl vs. LyzMCre-Hmox1fl/fl) measured with Cytometric Bead Array (CBA) analysis (n = 4, p = 0.0005). (B) MCP-1 concentrations in culture medium at ZT12 (= 12 h after medium change) after blood treatment in PMG (Hmox1fl/fl vs. LyzMCre-Hmox1fl/fl) measured with Cytometric Bead Array (CBA) analysis (n = 4, p = 0.0024). (C) MCP-1 concentration in cerebrospinal fluid (CSF) in human controls, on day 1 and day 7 post-SAH (control vs. day 1 p = 0.0004 and day 7 p = 0.0214, day 1 vs. day 7 p < 0.0001). (D) MCP-1 concentration on day 7 in human CSF and correlation to Per-2 mRNA expression Index CSF/blood on day 7 (r2 = 0.3061, p = 0.0023). (E) MCP-1 concentration on day 7 in human CSF correlation to Per-2 mRNA expression Index CSF/blood on day 14 (r2 = 0.5445, p = 0.0366). (F) MCP-1 concentration on day 1 in human CSF correlation with SAH severity (Hijdra) (r2 = 0.1998, p = 0.0194). (G) MCP-1 concentration on day 1 in human CSF correlation with SAH severity (WFNS) (r2 = 0.1562, p = 0.0413). (H) MCP-1 concentration on day 7 in human CSF correlation with SAH severity (WFNS) (r2 = 0.4795, p = < 0.0001). (I) MCP-1 concentration on day 7 in human CSF correlation with SAH severity (Hunt & Hess) (r2 = 0.2346, p = 0.0078). (J) MCP-1 concentration on day 7 in human CSF correlation with mRS at admission (r2 = 0.2998, p = 0.0021). (K) MCP-1 concentration on day 7 in human CSF correlation with mRS at discharge (r2 = 0.1490, p = 0.0386). Statistical analysis by unpaired t-test (A-B), Mann-Whitney test (C control vs. day 1 or day 7), Wilcoxon test (C day 1 vs. day 7) or simple linear regression and correlation (D-K). Statistically significant values were defined as p ≤ 0.05 (* p ≤ 0.05; ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001)